In the evolving field of bioinformatics, staying current is a challenge. For MiLaboratories, the challenge was creating software called Platforma.bio, which not only simplifies the complex analysis of immunogenomic data for researchers, but furthers the technology critical for drug discovery, especially in the field of mRNA vaccines and oncovaccines.
The recent launch of Platforma software is accompanied by the April announcement of partnerships with Miltenyi Biotech, whose robust production and commercialization capabilities will fast-track the adoption of full cycle next generation therapies for patients.
Jürgen Schmitz, managing director at Miltenyi Biotec, stated in an April press release: “We are thrilled to partner with MiLaboratories, a company that shares our commitment to advancing human health. Their RNA kits technology for immune sequencing complements our molecular analysis product portfolio perfectly. Moreover, their software solutions will offer our customers unparalleled support in data analysis. Together, we are building the future for next-generation therapies.”
Tailoring treatments to the patient
According to the team behind Platforma.bio, cancer vaccines, or oncovaccines, represent a leap forward in cancer treatment. The vaccines—which are tailored to each patient’s unique tumor profile—are designed to train the immune system to recognize and combat cancer cells by targeting specific tumor antigens. The sophisticated analysis of immunogenomic data that is provided by Platforma.bio’s software then enables the identification of these unique antigens, and the development of personalized vaccines.
The software aims to work to cure previous diseases with a data-heavy approach. With its hassle-free interactive and reproducible analysis, Platforma.bio allows for seamless and efficient interactions with smart resource utilization, which ensures that computations are performed only when changes occur. Designed from the ground up, the software can run on your desktop, a server, or an HPC or cloud infrastructure. It can help aid in the discovery of antibodies and TCR, single cell analysis, as well as vaccine development and immune tracking. MiLaboratories offers Platforma.bio for free to academic users.
Series A fundraising and growth
MiLaborites has announced Series A funding of $10M from a syndicate of venture funds, lead by Kfund, which will fuel further partnerships and scaling efforts. With goals to become the number one software solution for computational biology, Platforma.bio offers a seamless environment and flexible user-friendly interface, that provides an opportunity to create biological algorithmic blocs for any user or programmer. These blocks can be used by biologists for R&D, where unrestricted free for academic license increases popularity among PhD students and university labs.
Future vision
By utilizing advancements in artificial intelligence and machine learning, MiLaboratories aims to elevate Platforma.bio’s capabilities for antibody discovery, as well as for new drug development. Aiming to become leading names in the field of immunogenic analysis and personalized medicine, MiLaboratories and their previouse software MiXCR could eventually represent not just tools, but a new generation of precise, data-driven, and patient-centric care.
With continuous innovation, strategic partnerships, and a commitment to make an impact on patient outcomes, MiLaboratories is set to progress the outcome in personalized treatments and cures for patients, driving the future of personalized medicine and groundbreaking therapies.
This article is for informational purposes only and does not substitute for professional medical advice. If you are seeking medical advice, diagnosis or treatment, please consult a medical professional or healthcare provider.
VentureBeat newsroom and editorial staff were not involved in the creation of this content.
